Arm-crank Exercise Training on Cardiovascular Function of Patients With Peripheral Artery Disease
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03837639 |
Recruitment Status :
Suspended
(The study was suspended indefinitely because of Covid-19.)
First Posted : February 12, 2019
Last Update Posted : March 31, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Peripheral Arterial Disease Intermittent Claudication Hypertension | Other: Arm ergometer Other: Treadmill ergometer Other: Control group | Not Applicable |
Arm-crank exercise (ACT) is an alternative exercise strategy for patients with symptomatic peripheral artery disease (PAD) due the benefits on functional capacity and quality of life, besides provoking less or no pain symptoms during the execution. This study sought to describe the protocol of a study that will analyse the effect of ACT exercise on walking capacity, cardiovascular function, cognition and quality of life in patients with symptomatic PAD.
This is a three-armed randomized, prospective, single-blind data collection, single-center, controlled study enrolling 45 patients with symptomatic PAD which will be randomized into 3 intervention groups: walking training (WT), ACT (WT and AC: 15 to 10 sets of 2 to 5 minutes, Borg 13 to 15) and control group (CG). Before and after 12 weeks of intervention, cardiovascular function (ambulatory blood pressure , clinic blood pressure, central blood pressure, heart rate variability, arterial stiffness, vascular function), functional capacity (six-minute walking test, 2 minute step test [2 MST], Walking impairment questionnaire [WIQ], Walking estimated limitation calculated by history [WELCH], Baltimore activity scale for intermittent claudication, handgrip test and short physical performance battery [SPPB]), cognition (executive function and memory) and quality of life (short version of world health organization quality of life and vascular quality of life questionnaire [VASCUQOL-6]) will be assessed.
This is the first trial to evaluate the effects of ACT on regulatory mechanisms of cardiovascular system in PAD patients. If the results are as expected, they will provide evidence of ACT in promoting cardiovascular benefits in symptomatic PAD population.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 45 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Effects of Arm-crank Exercise Training on Cardiovascular Function of Patients With Peripheral Artery Disease: a Randomized Controlled Trial |
Actual Study Start Date : | June 10, 2019 |
Estimated Primary Completion Date : | December 10, 2021 |
Estimated Study Completion Date : | December 10, 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: Arm crank ergometer
Arm-crank exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard.
|
Other: Arm ergometer
Arm-crank exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard |
Experimental: Treadmill ergometer
Walking exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard.
|
Other: Treadmill ergometer
Walking exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard. |
Control group
Patients randomized to control group will attend to meetings with the researcher team twice a week during the 12 weeks. At these meetings, patients will perform manual tasks, with or without the use of artistic materials, cultural programs, cooking classes and home care, without any exercise component. This CG practice will be performed in order to minimize the effects of the patient's bi- weekly commitment and displacement to the training site, to minimize the influence of the patient- researcher contact and also minimize the convivial effect among the patients themselves, which will occur in the other two groups.
|
Other: Control group
Patients randomized to control group will attend to meetings with the researcher team twice a week during the 12 weeks. At these meetings, patients will perform manual tasks, with or without the use of artistic materials, cultural programs, cooking classes and home care, without any exercise component. This CG practice will be performed in order to minimize the effects of the patient's bi- weekly commitment and displacement to the training site, to minimize the influence of the patient- researcher contact and also minimize the convivial effect among the patients themselves, which will occur in the other two groups. |
- ambulatory blood pressure [ Time Frame: Change from baseline in ambulatory blood pressure at 12 weeks ]Systolic, diastolic and mean blood pressure will be measured before and after 12 weeks of intervention period on intervention and control group by an automatic ambulatory blood pressure monitor (Cardios, São Paulo, Brazil).
- Clinic blood pressure [ Time Frame: Change from baseline in ambulatory blood pressure at 12 weeks ]Systolic and diastolic brachial blood pressure will be measured before and after 12 weeks of intervention period on intervention and control group by an automatic blood pressure monitor (HEM-742, Omron Healthcare, Japan).
- Central blood pressure [ Time Frame: Change from baseline in ambulatory blood pressure at 12 weeks ]Systolic and diastolic central blood pressure will be measured before and after 12 weeks of intervention period on intervention and control group by an automatic blood pressure monitor (HEM-742, Omron Healthcare, Japan).
- Heart rate variability [ Time Frame: Change from baseline in ambulatory blood pressure at 12 weeks ]Heart rate variability will be measured before and after 12 weeks of intervention period on intervention and control group by heart rate monitor (Polar, RS 800, USA).
- Arterial stiffness [ Time Frame: Change from baseline in arterial stiffness at 12 weeks ]Carotid femoral pulse wave velocity will be measured before and after 12 weeks of intervention period on intervention and control group by pulse wave velocity measurement with applanation tonometry (SphygmoCor, AtCor Medical, Australia).
- Vascular function [ Time Frame: Change from baseline in flow-mediated vasodilation at 12 weeks ]Flow-meadiated dilation will be measured before and after 12 weeks of intervention period on intervention and control group by a flow mediated dilation measurement with an ultrasound image (HDI 5000 Sono CT, Philips, The Netherlands).
- Walking capacity [ Time Frame: Change from baseline in walking distance at 12 weeks ]Six-minute walking test will be measured before and after 12 weeks of intervention
- March in place [ Time Frame: Change from baseline in the number of the steps at 12 weeks ]Two-minute step test will be measured before and after 12 weeks of intervention
- Subjective measurement of walking capacity [ Time Frame: Change from baseline in the walking impairment questionnaire score after 12 weeks ]Walking impairment questionnaire will be measured before and after 12 weeks of intervention
- Subjective measurement of walking capacity compared to healthy subjects [ Time Frame: Change from baseline in the Walking estimated limitation calculated by history questionnaire score after 12 weeks ]Walking estimated limitation calculated by history questionnaire will be measured before and after 12 weeks of intervention
- Overall strength test [ Time Frame: Change from baseline in kgf of the handgrip test after 12 weeks ]Handgrip strength test will be measured before and after 12 weeks of intervention
- Symptoms of intermittent claudication [ Time Frame: Change from baseline in the Baltimore Activity Scale for Intermittent Claudication score after 12 weeks ]The Baltimore Activity Scale for Intermittent Claudication is a questionnaire that will be measured before and after 12 weeks of intervention.
- General functional capacity [ Time Frame: Change from baseline in the Short Physical Performance Battery score after 12 weeks ]The Short Physical Performance Battery will be measured before and after 12 weeks of intervention.
- Specific quality of life of vascular patients [ Time Frame: Change from baseline in the Vascular quality of life questionnaire score after 12 weeks ]The Vascular quality of life questionnaire will be measured before and after 12 weeks of intervention.
- General quality of life [ Time Frame: Change from baseline in the World Health Organization Quality of Life score after 12 weeks ]The World Health Organization Quality of Life questionnaire will be measured before and after 12 weeks of intervention

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 45 Years to 85 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- PAD stage II
- Ankle brachial index <0.90 in one or both lower limbs;
- Women in post-menopause phase without hormone replacement therapy
- Not an active smoker;
- Able to perform exercise training;
Patients selected to participate in the study will be only excluded if:
- Change their medication;
- Present any health impairment that contraindicates the practice of physical exercise during the study;

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03837639
Brazil | |
Hospital Israelita Albert Einstein | |
São Paulo, Brazil, 05652-900 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Hospital Israelita Albert Einstein |
ClinicalTrials.gov Identifier: | NCT03837639 |
Other Study ID Numbers: |
PAD01 |
First Posted: | February 12, 2019 Key Record Dates |
Last Update Posted: | March 31, 2020 |
Last Verified: | June 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | We are planing to share our data in the future. |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) Clinical Study Report (CSR) |
Time Frame: | After publication of the main paper. |
Access Criteria: | Ask to authors permision. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
arm-crank exercise training cardiovascular function |
Peripheral Arterial Disease Peripheral Vascular Diseases Intermittent Claudication Vascular Diseases |
Cardiovascular Diseases Atherosclerosis Arteriosclerosis Arterial Occlusive Diseases |